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Background: Metabolic abnormalities have consistently been 
identified as a part of schizophrenic illness. With the introduction 
of second generation antipsychotics and their possible association 
with metabolic abnormalities, the interest in this topic has 
been renewed. Many studies have since then provided convincing 
evidence for a high risk of diabetes and other glucose abnormalities, 
the metabolic syndrome, lipid abnormalities, increased 
cardiovascular risk factors and mortality due to elevated cardiovascular 
risk in patients with schizophrenia. These metabolic 
abnormalities are of major clinical concern, not only because 
of their direct, somatic effects on morbidity and mortality, but 
also because of their association with psychiatric outcome, such 
as a higher prevalence of psychotic and depressive symptoms, 
a lower functional outcome, a worse perceived physical health 
and lower adherence to medication. The reasons that underlie 
the high prevalence of these metabolic abnormalities are much 
debated, especially when considering the possible role of secondgeneration, 
‘atypical’ antipsychotics in the occurrence of these 
abnormalities. Clinical trial data, evaluating patients with fasting 
blood samples, suggest a metabolic safe profile for aripiprazole. 
Method: A large scale metabolic study is ongoing at our 
University hospital in Belgium. The metabolic safety of aripiprazole 
was evaluated in a prospective naturalistic study. All 
patients started on aripiprazole underwent an extensive metabolic 
evaluation, including an oral glucose tolerance test (OGTT), at 
baseline, at 6 weeks and at 3 months follow-up. 30 schizophrenic 
patients were included in the study. 5 patients met criteria for 
diabetes on their previous antipsychotic treatment at the moment 
of switch to aripiprazole. 
Results: At 3 months follow-up there was a significant reduction 
in weight and waist circumference. There was a significant 
reduction in fasting glucose, fasting insulin, insulin resistance 
and serum lipids (cholesterol, triglycerides, LDH and non-HDL 
cholesterol). There was also a significant reduction of prolactin. 
All cases of recent onset diabetes were reversible at 3 months 
follow-up. Four patients had normal glucose values fasting and 
at 120 min in the OGTT. One patient had impaired glucose 
tolerance at endpoint. There were no new cases of emergent 
glucose abnormalities during treatment with ariprazole. There was 
a significant reduction in the prevalence of ATP-III metabolic 
syndrome comparing baseline with endpoint (p = 0.0011). 
Conclusion: The importance of actively screening for 
metabolic abnormalities needs to be stressed and, by consequence, 
the widespread use of adequate screening guidelines is crucial. In 
choosing between antipsychotic agents the risk-benefit evaluation 
taking metabolic side-effects is important. This evaluation should 
also take the existing metabolic risk-factors of the individual 
patient into account. Our prospective data confirm the metabolic 
safety of aripiprazole, both on glucose homeostasis and lipids. 
Our results support the reversibility of recent onset diabetes on 
antipsychotic medication, if detected early and when switch is 
done to a safer metabolic antipsychotic. 
 
